FDA approves weight loss drug Zepbound to treat obstructive sleep apnea

(By Juliana Kim for NPR)

The weight loss drug Zepbound has become the first prescription medication approved to treat obstructive sleep apnea.

The Food and Drug Administration on Friday authorized the use of Zepbound, made by Eli Lilly & Co., for adults with obesity and moderate to severe obstructive sleep apnea (OSA), a common condition where a person struggles to breathe properly during sleep. The federal agency advises that the drug is used in combination with a reduced-calorie diet and increased exercise. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.